Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05451368
Other study ID # plz333333
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 17, 2022
Est. completion date March 31, 2023

Study information

Verified date July 2022
Source Shenyang Northern Hospital
Contact geng wang, M.D.
Phone 13309886393
Email wanggeng69@163.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Previous studies have suggested that restenosis (RS) after stenting is mainly due to smooth muscle cell proliferation and migration, but recent evidence suggests that in-stent restenosis(ISR) is associated with a number of factors. Coronary artery calcification is an independent predictor of ischaemia-mediated revascularisation 1 year after percutaneous coronary intervention (PCI) following RS.The characteristics of new neointima in patients with in-stent restenosis of calcified lesions are important issues to explore


Description:

The characteristics of the endothelium after DES following implantation of calcified lesions have always been of interest to us. Its inherent peculiarities make the new endothelium of calcified lesions different. Firstly, the presence of calcification makes the neointima heal slowly. In addition DES has an anti-proliferative effect, which further diminishes the healing ability of the neointima of calcified lesions and impairs the barrier function of the endothelium. This may have a similar pathway to the formation of neointimal atherosclerosis or heterogeneous endothelium within the neointima. Secondly, stents with calcified lesions can be accompanied by incomplete stent expansion, stent fracture and stent misalignment. These conditions may accelerate the occurrence of restenosis within the stent. Thirdly, there are different types of calcified lesions. Different types of calcified lesions may heal and restenosis in different ways. It is therefore understood that calcified lesion healing has a number of pathways that exist in contradiction. These are issues that need to be explored in depth.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date March 31, 2023
Est. primary completion date February 28, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. The patient is older than 18 years. 2. The patient had undergone coronary angiography at our hospital for PCI and had first ISR with drug-eluting stent implantation. 3. Calcified lesion greater than 5 mm in length. 4. Stent implantation time greater than 30 days. Exclusion Criteria: 1. Bridge vessel lesions following coronary artery bypass grafting. 2. Planned modification of the DAPT regimen for medical reasons or other surgical procedures requiring modification within 3 months of the index procedure. 3. Patients undergoing heart transplantation. 4. Significant angiogenic lesions in the target vessel that may prevent stent delivery and deployment. 5. Bifurcation disease lesions involving collateral branches = 2.5 mm in diameter. 6. Lesions deemed by the investigator to be unsuitable for OCT imaging (e.g., extremely curved, very distal lesions). 7. Serum creatinine > 2.0 mg/dl at the time of treatment. 8. Greater than three types of stent implantation. 9. Subjects with malignancy or other co-morbidities (i.e., severe liver, kidney, lung, or pancreatic disease with a life expectancy of less than 18 months or which may result in protocol non-compliance).

Study Design


Intervention

Other:
Coronary artery calcification lesions
Calcification of atherosclerosis, a complex, organic, regulated and active process, is one of the manifestations of atherosclerosis. The progression of coronary atherosclerosis is a strong independent predictor of future coronary events. It has been shown that coronary artery calcification affects the healing of the neointima and the function of the endothelium after stenting. This may lead to changes in neointimal morphology and the development of neoatherosclerosis after stent implantation.

Locations

Country Name City State
China ShenyangNH Shenyang Liaoning

Sponsors (1)

Lead Sponsor Collaborator
Shenyang Northern Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean lumen area Quantitative Indicators,the mean area bounded by the luminal border on OCT(Optical Coherence Tomography) through study completion, an average of 1 year
Primary Minimum lumen area Quantitative Indicators,the minimum area bounded by the luminal border on OCT through study completion, an average of 1 year
Primary Maximum lumen area Quantitative Indicators,the maximum area bounded by the luminal border on OCT through study completion, an average of 1 year
Primary Percent area stenosis Quantitative Indicators,the (reference lumen area minus the minimum lumen area) divided by the reference lumen area, multiplied by 100. The reference segment used should be specified (proximal, distal, largest or average) on OCT through study completion, an average of 1 year
Primary Mean stent area Quantitative Indicators,the mean area bounded by the stent border on OCT through study completion, an average of 1 year
Primary Minimum stent area Quantitative Indicators,the Minimum area bounded by the stent border on OCT through study completion, an average of 1 year
Primary Maximum stent area Quantitative Indicators,the Maximum area bounded by the stent border on OCT through study completion, an average of 1 year
Primary lipid-laden intima Qualitative indicators,a diffusely bordered, signal-poor region with overlying signal-rich bands in the intima on OCT.the investigators measured its incidence on OCT. through study completion, an average of 1 year
Primary Calcification Qualitative indicators,shows a well-delineated, signal-poor region with sharp borders.the investigators measured its incidence on OCT. through study completion, an average of 1 year
Primary Thrombi Qualitative indicators,masses protruding into the lumen and discontinuous from the surface of the vessel wall.the investigators measured its incidence on OCT. through study completion, an average of 1 year
Primary Intimal rupture Qualitative indicators,discontinuity of the fibrous cap connecting the lumen.the investigators measured its incidence on OCT. through study completion, an average of 1 year
Primary Neovascularization Qualitative indicators,the presence of signal-poor holes or tubular structures with a diameter of 50 to 300 µm that are not connected to the vessel lumen.the investigators measured its incidence on OCT. through study completion, an average of 1 year
Primary Thin-cap fibroatheroma (TCFA) containing intima was defined as fibrous cap thickness =65 µm at the thinnest segment and an angle of lipid tissue =180°.the investigators measured its incidence on OCT. through study completion, an average of 1 year
Primary Macrophage infiltration Qualitative indicators,a bright spot with a high signal variance from the surrounding tissue.the investigators measured its incidence on OCT. through study completion, an average of 1 year
Primary Stent underexpansion Qualitative indicators,Stent expansion describes the minimum stent cross-sectional area either as an absolute measure (absolute expansion), or compared with the predefined reference area, which can be the proximal, distal, largest, or average reference area (relative expansion).the investigators measured its incidence on OCT. through study completion, an average of 1 year
Primary stent fracture Qualitative indicators,the interruption of stent continuity.the investigators measured its incidence on OCT. through study completion, an average of 1 year
Primary Uncovered struts the ratio of uncovered-to-total stent struts per section was calculated and expressed as percent on OCT. through study completion, an average of 1 year
Primary neoatherosclerosis neoatherosclerosis were defined by the presence of one or more of the following: lipid laden tissue ,thin-cap fibroatheroma (TCFA),neointimal calcification,Macrophage infiltration.the investigators measured its incidence . through study completion, an average of 1 year
See also
  Status Clinical Trial Phase
Unknown status NCT02498457 - The Effects and Safety of Low Calcium Dialysis on Coronary Artery Calcification in Maintenance Hemodialysis Patients N/A
Completed NCT00379899 - ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis Phase 4
Completed NCT03314493 - Prevention of the Progression of Coronary Calcification With Use of Spironolactone in Peritoneal Dialysis Patients Phase 3
Recruiting NCT05346068 - The Value of IVL Compared To OPN Non-Compliant Balloons for Treatment of RefractorY Coronary Lesions (VICTORY) Trial N/A
Completed NCT02966028 - Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD) Phase 2
Completed NCT01992848 - MAP-Calcification: MicroRNAs as Potential Biomarkers for Coronary Artery Calcification N/A
Recruiting NCT06181240 - Modification of Coronary Calcium With Laser Based Intravascular Lithotripsy for Coronary Artery Disease (FRACTURE) N/A
Terminated NCT05508893 - Screening for Coronary Artery Disease USing Primary Evaluation With Coronary CTA in Aviation Medicine (SUSPECT) N/A
Recruiting NCT06075602 - COMPLEX Registry - A Prospective COhort Study to Describe the Management and Outcomes of Patients Presenting With compLEX and Calcified Coronary Artery Disease
Completed NCT05112250 - IVL for Stent Underexpantsion
Not yet recruiting NCT06379295 - Coronary Artery Calcification Assessed on PET/CT
Completed NCT02913144 - 7 Year Follow-up Study of the DanRisk Population N/A
Completed NCT00860847 - Firefighter Aged Garlic Extract Investigation With CoQ10 as a Treatment for Heart Disease (FAITH) Phase 3
Not yet recruiting NCT04319666 - Intravascular Balloon Lithotripsy in Left Main Stem Percutaneous Coronary Intervention N/A
Completed NCT03967366 - Melatonin and Coronary Artery Calcification
Recruiting NCT05818098 - Coronary Intravascular Lithotripsy System in Patients With Coronary Artery Calcification (VIGOUR) N/A
Recruiting NCT05283538 - Comparison of Cardiovascular Risk Stratification in Young People With Type 1 Diabetes by Coronary Calcium Score to ESC/ESA2019 Recommendations N/A
Recruiting NCT04742478 - ROVUS Asia Registry (Evaluate Safety and Effectiveness of Rotational Atherectomy and Intravascular Ultrasound for Heavily Calcified Coronary Lesion)
Recruiting NCT05259046 - The InterVitaminK Trial - Effects of Vitamin K Supplementation on Cardiovascular, Metabolic, and Bone Health N/A
Recruiting NCT01101698 - Vitamin K2 and Vessel Calcification in Chronic Kidney Disease Patients Phase 4